News

BioSpace17h
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...
Citi Maintains a Hold Rating on Pfizer (PFE) Amidst Pricing Policy Headwinds
On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of ...
National Law Review6h
The Trump Administration Announces Price Targets as It Takes a Second Swing at “Most Favored Nation” Drug Pricing Model
The EO revives effort to link U.S. drug prices to those in peer countries, calling for voluntary industry action. Aggressive ...
Covid Vaccine Boosters Won’t Be Available for Healthy Adults Under 65. How Will That Work?
On May 20, U.S. Food and Drug Administration ( FDA) officials announced that Covid-19 vaccines will no longer be available to everyone. Instead, annual boosters will be limited to people ages 65 and ...